PlumX Metrics
Embed PlumX Metrics

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Journal of Experimental Medicine, ISSN: 1540-9538, Vol: 215, Issue: 3, Page: 859-876
2018
  • 161
    Citations
  • 0
    Usage
  • 296
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming toward a proinflammatory activation state represent different strategies to therapeutically target this abundant myeloid population. In this study, we report that inhibition of colony-stimulating factor-1 receptor (CSF-1R) signaling sensitizes TAMs to profound and rapid reprogramming in the presence of a CD40 agonist before their depletion. Despite the short-lived nature of macrophage hyperactivation, combined CSF-1R+CD40 stimulation of macrophages is sufficient to create a proinflammatory tumor milieu that reinvigorates an effective T cell response in transplanted tumors that are either responsive or insensitive to immune checkpoint blockade. The central role of macrophages in regulating preexisting immunity is substantiated by depletion experiments, transcriptome analysis of ex vivo sorted TAMs, and gene expression profiling of whole tumor lysates at an early treatment time point. This approach enabled the identification of specific combination-induced changes among the pleiotropic activation spectrum of the CD40 agonist. In patients, CD40 expression on human TAMs was detected in mesothelioma and colorectal adenocarcinoma.

Bibliographic Details

Hoves, Sabine; Ooi, Chia-Huey; Wolter, Carsten; Sade, Hadassah; Bissinger, Stefan; Schmittnaegel, Martina; Ast, Oliver; Giusti, Anna M.; Wartha, Katharina; Runza, Valeria; Xu, Wei; Kienast, Yvonne; Cannarile, Michael A.; Levitsky, Hyam; Romagnoli, Solange; De Palma, Michele; Rüttinger, Dominik; Ries, Carola H.

Rockefeller University Press

Medicine; Immunology and Microbiology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know